Designing effective containment strategies for the next generation of HPAPI manufacturing

With early risk assessment, engineered controls and skilled teams underpinning safe, scalable production, growing demand for potent therapies is driving integrated manufacturing partnerships

You need to be a subscriber to read this article.
Click here to find out more.

Highly potent APIs (HPAPIs) are defined by their ability to produce significant pharmacological effects at exceptionally low doses (often in the microgram or even nanogram range).

Designing effective containment strategies for the next generation of HPAPI manufacturing

In recent years, HPAPIs have become increasingly important in targeted therapies, with the HPAPI market projected to be worth $32.02 billion in 2026 and rising to $49.59 billion by 2031.

This growth is being driven by the shift toward precision medicine, with oncology remaining the most influential therapeutic area. 

Hongfeng Chen, Executive Vice President of Process Chemistry at Wilmington PharmaTech, reports.

Owing to their inherent toxicity, HPAPIs have very low occupational exposure limits (OELs) — typically below 10 µg/m³ during an 8‑hour time‑weighted average — which creates significant safety, environmental and manufacturing challenges.

Cytotoxic compounds, a subset of HPAPIs commonly used in targeted cancer therapies, present even greater risk because of their mechanism of action and extreme potency. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like